- 1762-P - THDB0206 Injection (BioChaperone Lispro, BCLIS) Improves Postprandial and Daily Glucose Control vs. Lispro (LIS) in Chinese Patients with Type 2 Diabetes (T2D) [Board No. 1762]
-
ePoster Theater B (Halls B1-C)1762-P
Q.Wang: Employee; Current; Tonghua Dongbao Pharmaceutical Co., Ltd.. C.Mégret: Employee; Current; ADOCIA, Stock/Shareholder; Current; ADOCIA. L.Zhang: Employee; Current; Tonghua Dongbao Pharmaceutical Co., Ltd.. M.Gaudier: Employee; Current; ADOCIA, Stock/Shareholder; Current; ADOCIA. C.Pei: Employee; Current; Tonghua Dongbao Pharmaceutical Co., Ltd.. O.Soula: Board Member; Current; ADOCIA, Employee; Current; ADOCIA, Stock/Shareholder; Current; ADOCIA. T.Heise: Consultant; Current; Gan & Lee Pharmaceuticals, i2o Therapeutics, Other - Travel Grants; Current; Zealand Pharma A/S, Research Support; Current; Betagenon AB, Civica, Corteria Pharmaceuticals, DioGenX, ENYO Pharma, Gan & Lee Pharmaceuticals, Nanexa, Neodyne Biosciences, Sam Chun Dang, Sun Pharmaceutical Industries Ltd., Zealand Pharma A/S, AstraZeneca, Biocon, Eli Lilly and Company, Novo Nordisk, Roche Diagnostics, Research Support; Ended; Afon Technology, Cytoki Pharma, Liom, Speaker's Bureau; Current; Eli Lilly and Company, Novo Nordisk. X.Li: Consultant; Current; Tonghua Dongbao Pharmaceutical Co., Ltd..TypeTrackTopic
Enter Note
Go to previous page in this tab
Session
